Cantargia (CANTA) investor relations material

Strategic financing and allocation

• Raising SEK 125 million through a rights issue and SEK 75 million via a loan agreement, totaling up to SEK 199 million to accelerate development priorities and drive growth.

• Proceeds will advance core clinical programs, particularly nadunolimab, through critical milestones and reinforce its role as a backbone therapy.

• Rights issue offers two new shares for every nine held at SEK 2.25 per share, with a 20% discount to TERP and supported by subscription undertakings and guarantees covering about 60% of the issue.

• Loan agreement with Fenja Capital provides SEK 75 million at a minimum 10% interest rate, maturing in 2028, with warrants for 3% dilution.

• Combined financing extends the cash runway to mid-2028.

Clinical development and portfolio progress

• Nadunolimab is positioned for combination studies in PDAC, targeting rational approaches with RAS and MEK inhibitors, leveraging high IL1RAP expression in KRAS-mutated tumors.

• Early clinical data from a Phase 1b/2a study in high-risk MDS show all evaluable patients achieved complete remission in Phase 1b.

• The MDS/AML study is advancing to Phase 2a, aiming to enroll about 40 patients.

• Expansion into phase II-A will confirm findings and support further development, funded by the rights issue.

• Pipeline development continues with CAN14 and next-generation assets.

Strategic flexibility and future outlook

• Financing structure balances dilution and cost of capital, aiming to support value-creating milestones.

• Flexibility maintained for potential strategic partnerships or independent advancement of late-stage nadunolimab studies.

• Combination studies with RAS inhibitors are expected to show additive or synergistic effects due to non-overlapping mechanisms and tumor microenvironment targeting.

• Patient selection in early studies will not require IL1RAP pre-selection but will measure it retrospectively to inform future trial design.

• Late-stage study costs could reach $300 million for large trials, but current financing covers early-phase studies; future positioning will depend on evolving clinical landscape and competitor data.